Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... de noviembre de 2014  BioClinica®, Inc., un ... y tecnologías eClinical, ha indicado un aumento de ... para el seguimiento basado en el riesgo en ... concepto del seguimiento basado en el riesgo más ... de seguimiento o cambio de los métodos de ...
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)... SAN DIEGO , Nov. 21, 2014 /PRNewswire/ ... TNDM ), a medical device company and ... today announced a partnership with Tidepool, a non-profit ... an open source software platform that increases diabetes ... the Tidepool Platform, which is currently under development, ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
... Codexis, Inc. (Nasdaq: CDXS ) today announced the ... to be held in New York, NY on May 18-19, ... will appear on a panel titled "Biofuels" scheduled for May ... not been provided by the conference organizers. Further information will ...
... Pa., May 4, 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... will participate in the Bank of America Merrill Lynch ... the Encore at Wynn Las Vegas.  Mr. Armando Anido, ... an overview of the Company and its product pipeline ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 2Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 3
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has ... . They are now offered at deeply discounted prices, ... from now to Dec. 15. The main purpose of the ... company’s high quality items are ideal options for ladies who ... of money. All its new mint cocktail dresses are very ...
(Date:11/23/2014)... TX (PRWEB) November 23, 2014 ... Devices Market 2006 to 2020 - Asia-Pacific” provides ... energy devices market segments: minimally invasive body contouring ... devices. The analysis includes market size data by ... for the following countries: China, Japan, South Korea, ...
(Date:11/23/2014)... 2014 Pro Ace Care, a renowned Vancouver ... now be providing an 8 year warranty on its selected ... installations went up due to the impending winter season, it ... of the premium service that the company provides. As a ... on John Wood and Bradford hot water tanks. , ...
(Date:11/23/2014)... (HealthDay News) -- Close friends have more influence on ... a new study says. "We,ve known for ... influence on individual alcohol use, but there are no ... and the friend group,s influence on those decisions," Jonathon ... Public Health, said in a university news release. ...
(Date:11/23/2014)... a notable magnetic locks maker, has released a variety ... available at low rates up to 30% off. ... emergency doors. The emergency door adopts fireproof material and ... colors. All of the products are top-quality guaranteed. ... as easy as many people think. As a ...
Breaking Medicine News(10 mins):Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Close Friends May Be Key to Teens' Drinking 2
... WuXi PharmaTech (Cayman) Inc.,(NYSE: WX ), a ... company with operations in China and the,United States, today ... to,the WuXi PharmaTech Board of Directors. , ... Dr. Ge Li, WuXi,s Chairman and ...
... Tenn., Feb. 5 Brookdale Senior Living Inc. (NYSE: ... Chief Executive Officer, and Mark Ohlendorf, Co-President and Chief ... at the UBS Global Healthcare Services Conference in New ... at 8:30 a.m. Eastern Time.The presentation is being audio ...
... WASHINGTON, Feb. 5 The following statement of ... was released today:(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The smoke-free restaurant ... all workers and the public from the proven ... Virginia House and Senate to reject this bill ...
... 5, 2009 Narcotics have an irreversible effect on ... according to Dr. Stphane Potvin of the Universit de ... Lafontaine Hospital. , According to his research, some ... from drug addiction. The study has shown that drug ...
... 5 The following is a statement in response ... Bader Ginsburg being diagnosed with pancreatic cancer from Julie ... Network, the only national organization creating hope in a ... advocacy for a cure. "Our thoughts are with ...
... 5 /PRNewswire/ -- As the strain of ... Quorum Health Resources (QHR) has announced the launch of ... subsidiary that provides hospitals and health systems with short-term, ... challenges are great, according to the American Hospital Association,s ...
Cached Medicine News:Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 2Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 3Health News:Virginia Leaders Should Reject Flawed Smoke-Free Legislation That Fails to Protect Everyone's Right to Breathe Clean Air 2Health News:Early Detection Methods for Pancreatic Cancer Urgently Needed: A Statement From the Pancreatic Cancer Action Network 2Health News:Intensive Resource Group (IRG) Helps Hospitals Address Financial and Operational Crisis 2Health News:Intensive Resource Group (IRG) Helps Hospitals Address Financial and Operational Crisis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: